Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

By sjmartinez • August 18, 2023

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498-y. Epub ahead of print. PMID: 37592104.

Tags: Dermatology, Hematology/Oncology, Publications

Probing DNA damage in Rett syndrome neurons uncovers a role for MECP2 regulation of PARP1

Morales A, Korsakova E, Mansooralavi N, Ravikumar A, Rivas G, Soliman P, Rodriguez L, McDaniel T, Lund A, Cooper B, Bhaduri A, Lowry WE. Probing[...]

Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of two patients

Galamgam J, Baroni E, Tsai S, Cheng CE. Improvement of pruritus associated with erythrocytosis in transmasculine patients undergoing gender-affirming therapy with phlebotomy: a report of[...]

Landscape of dermatology education in allopathic medical schools across the United States

Poppens M, McClain W, Collier E, Cheng K, Hogeling M. Landscape of dermatology education in allopathic medical schools across the United States. Dermatol Online J.[...]